U.S. :
+1-206-701-6702
UK :
+44-020-8133-4027
JAPAN :
+81-50-5539-1737
INDIA :
+91-848-285-0837
Press Release: Global Nasal Drug Delivery Systems Market to Surpass US$ 75 billion by 2026
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Nasal Drug Delivery Systems Market Insights – An Effective Needle-free Solution for Drug Delivery
Nasal drug delivery system is an alternative to invasive administrations and provides direct access to systemic circulation. Intranasal drug delivery is common and most preferred route of administration in treatment of allergic and non-allergic rhinitis, pain, acute treatment of migraine, and nasal congestion associated with sinusitis, common cold or rhinitis. Nasal drug delivery are mostly used in case wherein rapid onset of action is required, or to reach the site where other route of administration displays ineffective results. Nasal drug delivery is also preferred route for needle-free vaccination and systemic drug delivery. Liquid nasal preparations can be administered through inhalers, droppers, spray pumps, nebulizers or atomizers.
The global nasal drug delivery systems market size is estimated to be valued at US$ 48.1 billion in 2018 and is expected to witness a CAGR of 6.3% over the forecast period (2018 – 2026).
Figure 1. Global Nasal Drug Delivery Systems Market Share (%), By Region
Source: Coherent Market Insights Analysis (2018)
Increasing awareness about advantages of nasal drug delivery is driving the nasal drug delivery systems market growth
Major advantages of nasal drug delivery is that, the drug circumvents hepatic first-pass metabolism, leading to high bioavailability as compared to drug administered orally. On the other hand, parenteral route of administration is also inconvenient for long term therapeutic treatment.
Nasal cavity being highly vascular enhances the drug absorption resulting in rapid onset of action. Moreover, ease of administration coupled with non-invasive method is driving adoption of nasal drug delivery systems, in turn propelling nasal drug delivery systems market growth.
However, limitations associated with nasal drug delivery system such as histological toxicity or lesser area of absorption as compared to orally administered drug hinders the nasal drug delivery systems market growth.
Figure 2. Global Nasal Drug Delivery Systems Market Value (US$ Mn), By Region, 2017
Source: Coherent Market Insights Analysis (2018)
Furthermore, increasing product launches with nasal drug delivery is also fueling the nasal drug delivery systems market growth. For instance, in 2017, Optinose, an ENT / Allergy specialty pharmaceutical company, received New Drug Application approval for its Xhance, fluticasone propionate, for the indication of nasal polyps in adults. Xhance is a specially designed combination of novel Optinose Exhalation Delivery System and an aqueous suspension of microfine drug delivery for topical intranasal administration via a metered atomizing spray pump. Moreover, the product can be opted for powder and liquid formulation and also addresses the limitation of traditional nasal spray by using its bi-directional delivery.
Nasal drug delivery systems market regional outlook - Asia Pacific is expected to be a rapidly growing market over the forecast period
The regional nasal drug delivery systems market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa by Coherent Market Insights. North America nasal drug delivery systems market is estimated to hold dominant position in 2017. The factors attributed to growth of the North America in nasal drug delivery systems market is increasing research and development by local manufacturers to develop new drug device or delivery system combination.
For instance, Impel NeuroPharma, Inc., a Seattle-based clinical stage biotechnology company, is engaged in applying its Precision Olfactory Delivery (POD) nasal drug delivery platform for drugs such as levodopa powder, insulin liquid, and olanzapine powder for the treatment of Parkinson’s disease, Alzheimer’s disease and agitation in schizophrenia and bipolar disorder, respectively.
However, Asia Pacific nasal drug delivery systems market is expected to witness rapid growth, owing to increasing prevalence of diseases, which are expected to be treated by intranasal route of drug delivery. For instance, according to Journal of Allergy and Clinical Immunology, 2017, the prevalence of asthma in developed cities of Asia Pacific such as Hong Kong, Japan, and Singapore is as high as 12.4%. Key players are targeting high patient pool in this region for further growth, which is not expected in matured markets such as North America and Europe.
The major players operating in nasal drug delivery systems market are Merck & Co., GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Baxter International, Inc., Valeant Pharmaceuticals International, Inc., Becton, Dickinson and Company, and Novartis AG.
Nasal cavity is becoming one of the most potential and promising route of drug delivery, owing to its advantages such as bypassing the hepatic first-pass metabolism, and most importantly patient convenience. The report provides in depth understanding of developing intranasal formulation to achieve better therapeutic objective, in turn drive the market share. However, the report also focuses on the practical and technical factors which remains the hindrance for the global nasal drug delivery system market growth over the forecast period. Furthermore, report tracks and forecast the market growth of each segment for the period of 2016-2026.
Market Dynamics
The major factors driving growth of the nasal drug delivery systems market includes, increasing product launches coupled with technologically advanced drug delivery systems and increasing incidence of nasal cavity associated diseases. For instance, in June 2018, Insys Therapeutics, Inc., a specialty pharmaceutical company, conducted clinical trial for epinephrine nasal spray, an alternative for intramuscular injection for the indication of anaphylaxis. Furthermore, companies have large number of pipeline drugs, which are to be delivered intranasally such as Acerus Pharmaceuticals Corporation is investigating TEFINA, a testosterone nasal gel, for addressing the unmet treatment demand for female sexual dysfunction. However, intranasal route of drug delivery is not suitable for all drug types, which is expected to be a major restrain for growth of the nasal drug delivery systems market.
Key features of the study:
Detailed Segmentation:
Global Nasal Drug Delivery Systems Market, By Dosage Form:
Global Nasal Drug Delivery Systems Market, By Container Type:
Global Nasal Drug Delivery Systems Market, By System Type:
Global Nasal Drug Delivery Systems Market, By Therapeutic Application:
Global Nasal Drug Delivery Systems Market, By Distribution Channel:
Global Nasal Drug Delivery Systems Market, By Region:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 40 market data tables and 38 figures on “Nasal Drug Delivery Systems Market - Global forecast to 2026”.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Sales Office (U.S.) : Coherent Market Insights Pvt Ltd, 1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Asia Pacific Intelligence Center (India) : Coherent Market Insights Pvt Ltd, 203, 2nd Floor,
Bremen Business Center, Aundh, Pune,
Maharashtra 411007, India.
UK :
+44-020-8133-4027
JAPAN :
+81-50-5539-1737
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
US :
INDIA :
UK :
JAPAN :
Contact Us
